下载文件内容简介：雅思阅读真题：Why did a promising heart drug fail?
Doomed drug highlights complications of meddling with cholesterol.
The failure of a high-profile cholesterol drug has thrown a spotlight on the complicated machinery that regulates cholesterol levels. But many researchers remain confident that drugs to boost levels of 'good' cholesterol are still one of the most promising means to combat spiralling heart disease.
Drug company Pfizer announced on 2 December that it was cancelling all clinical trials of torcetrapib, a drug designed to raise heart-protective high-density lipoproteins (HDLs). In a trial of 15000 patients, a safety board found that more people died or suffered cardiovascular problems after taking the drug plus a cholesterol-lowering statin than those in a control group who took the statin alone.
The news came as a kick in the teeth to many cardiologists because earlier tests in animals and people suggested it would lower rates of cardiovascular disease. "There have been no red flags to my knowledge," says John Chapman, a specialist in lipoproteins and atherosclerosis at the National Institute for Health and Medical Research (INSERM) in Paris who has also studied torcetrapib. "This cancellation came as a complete shock."......……
This passage has 7 paragraphs 1-7.Choose the correct heading for each paragraph from the list of headings below.
Write the correct number i-ix in boxes 1-7 on your answer sheet.
List of Headings
i.How does torcetrapib work?
ii.Contradictory result prior to the current trial
iii.One failure may possibly bring about future success
iv.The failure doesn’t lead to total loss of confidence